Sign In
Buy MYGN
$2.86
-2.51 (-46.74%)
At Close: Jul 31, 2026
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
09:15am, Thursday, 09'th Apr 2026
SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at
Myriad Genetics: SOTP Suggests The Company Is Undervalued
05:29pm, Tuesday, 31'st Mar 2026
Myriad Genetics, Inc. has grown from a mainly Hereditary Cancer business into a broader precision medicine company, but the market still values it at a low multiple because earnings, cash flow, and. T
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 25'th Mar 2026
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term
10:45am, Thursday, 19'th Mar 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
10:51am, Wednesday, 18'th Mar 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer
Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth
10:10am, Tuesday, 24'th Feb 2026
Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth despite modest revenue decline. MYGN's core franchises—Prolaris and hereditary cance
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down
08:45am, Tuesday, 24'th Feb 2026
Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
10:54pm, Monday, 23'rd Feb 2026
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings
09:00pm, Monday, 23'rd Feb 2026
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates
08:26pm, Monday, 23'rd Feb 2026
Myriad Genetics (MYGN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind 1 of $8.1 million
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
09:15am, Thursday, 19'th Feb 2026
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical val
Ahead of Myriad (MYGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:15am, Wednesday, 18'th Feb 2026
Besides Wall Street's top-and-bottom-line estimates for Myriad (MYGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quar
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
04:15pm, Monday, 16'th Feb 2026
SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings c
